by admin | 15 September 2022 | News
Prestigious ALS Association grant awarded to BWH to study the utility of an intranasal anti-CD3 monoclonal antibody in an animal model of Amyotrophic Lateral Sclerosis New York, September 15, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the... by admin | 9 September 2022 | News
New York, September 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its... by admin | 25 August 2022 | News
New York, August 25, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners... by admin | 17 August 2022 | News
New York, August 17, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited,... by admin | 1 August 2022 | News
– Study conducted in animal models of Alzheimer’s disease finds restored microglia homeostasis and improvement in cognition – New York, August 1, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company... by admin | 18 July 2022 | News
New York, July 18, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has appointed Matthew Davis, MD, RPh as its Chief... by admin | 15 July 2022 | News
New York, July 15, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors has accepted the voluntary... by admin | 17 June 2022 | News
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice New York, June 17, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of... by admin | 10 June 2022 | News
New York, June 10, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited,... by admin | 9 June 2022 | News
New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an... by admin | 8 June 2022 | News
A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment. These findings are consistent with the results obtained from the... by admin | 6 June 2022 | News
NEW YORK – June 6, 2022 – Tiziana Life Sciences Ltd (NASDAQ: TLSA) (“Tiziana” or the “Company”), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief... by admin | 1 June 2022 | News
New York, June 1, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced that Dr. Tanuja... by admin | 24 May 2022 | News
– Form 20-F Filed on May 23, 2022 Following Receipt of Notice from Nasdaq Regarding Filing Deadline of its Annual Report – New York, May 24, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology... by admin | 26 April 2022 | News
NEW YORK – 26 April 2022 – Tiziana Life Sciences Ltd (NASDAQ: TLSA) (“Tiziana” or the “Company”), a clinical-stage biopharmaceutical company developing alternative routes of immunotherapy with a focus on innovative drugs for neurodegenerative... by admin | 5 April 2022 | News
This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.Tiziana recently reported clinical data from the first SPMS patient showing... by admin | 25 March 2022 | News
This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn’s Disease, is anticipated to be completed by Q4, 2022.New York, March 25, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the... by admin | 16 March 2022 | News
Bioworld have published an article on Tiziana Life Sciences SPMS 6-month data using intranasal foralumab. by admin | 15 March 2022 | News
Multiple Sclerosis News Today has published an article regarding Foralumab effectively treating the first SPMS patient by admin | 15 March 2022 | News
New York, March 15, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announces the availability of the replay of its March 14 KOL event entitled... by admin | 11 March 2022 | News
Monday, March 14th @ 11 am ET, registration details below NEW YORK, March 11, 2022 – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today... by admin | 10 March 2022 | News
Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapyData show sustained inhibition of microglial activation as assessed by Positron Emission Tomography (PET)... by admin | 4 March 2022 | News
https://myemail.constantcontac… by admin | 1 March 2022 | News
New York, March 1, 2022 – Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate...